Sandbox:Roukoz: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
{|
{|
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases
! colspan="2" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases
| colspan="6" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations'''
| colspan="6" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations'''
! colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings
! colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings
Line 22: Line 22:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Unique features
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Unique features
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Cutaneous squamous cell carcinoma in situ (Bowen's disease)'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" rowspan="2" |'''Cutaneous squamous cell carcinoma in situ (Bowen's disease)'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Invasive squamous cell carcinoma'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Usually asymptomatic
* Usually asymptomatic
Line 68: Line 69:
| style="background: #F5F5F5; padding: 5px;" |same as above
| style="background: #F5F5F5; padding: 5px;" |same as above
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Keratoacanthoma'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" colspan="2"|'''Keratoacanthoma'''
| style="background: #F5F5F5; padding: 5px;" |Usually asymptomatic
| style="background: #F5F5F5; padding: 5px;" |Usually asymptomatic
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 102: Line 103:
* It is controversial whether keratoacanthomas represent a subtype of well-differentiated SCC or a separate entity
* It is controversial whether keratoacanthomas represent a subtype of well-differentiated SCC or a separate entity
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Merkel cell carcinoma'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" colspan="2" |'''Merkel cell carcinoma'''
| style="background: #F5F5F5; padding: 5px;" |Usually asymptomatic
| style="background: #F5F5F5; padding: 5px;" |Usually asymptomatic
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 120: Line 121:
| style="background: #F5F5F5; padding: 5px;" |Blue-red, dome-shaped nodule
| style="background: #F5F5F5; padding: 5px;" |Blue-red, dome-shaped nodule
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Nodular basal cell carcinoma'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" colspan="2"|'''Nodular basal cell carcinoma'''
| style="background: #F5F5F5; padding: 5px;" |Usually asymptomatic
| style="background: #F5F5F5; padding: 5px;" |Usually asymptomatic
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 133: Line 134:
| style="background: #F5F5F5; padding: 5px;" |Ulceration is frequent, and the term "rodent ulcer" refers to these ulcerated nodular BCCs
| style="background: #F5F5F5; padding: 5px;" |Ulceration is frequent, and the term "rodent ulcer" refers to these ulcerated nodular BCCs
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Superficial basal cell carcinoma '''
| style="background: #DCDCDC; padding: 5px; text-align: center;" colspan="2"|'''Superficial basal cell carcinoma '''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 148: Line 149:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Prurigo nodules'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" colspan="2"|'''Prurigo nodules'''
| style="background: #F5F5F5; padding: 5px;" |Usually asymptomatic
| style="background: #F5F5F5; padding: 5px;" |Usually asymptomatic
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 171: Line 172:
upper midback area is usually spared  
upper midback area is usually spared  
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Common nevus'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" colspan="2"|'''Common nevus'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 189: Line 190:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Blue nevus'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" colspan="2"|'''Blue nevus'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 208: Line 209:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Spitz nevus'''
| style="background: #DCDCDC; padding: 5px; text-align: center;"|'''Spitz nevus'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 221: Line 223:
| style="background: #F5F5F5; padding: 5px;" |benign, indolent melanocyte proliferation that most commonly develops in children, adolescents, and young adults.
| style="background: #F5F5F5; padding: 5px;" |benign, indolent melanocyte proliferation that most commonly develops in children, adolescents, and young adults.
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Solar lentigo'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" colspan="2"|'''Solar lentigo'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 234: Line 236:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Lentigo Maligna'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" colspan="2"|'''Lentigo Maligna'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 247: Line 249:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Lentigo Maligna Melanoma'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" colspan="2"|'''Lentigo Maligna Melanoma'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 260: Line 262:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Sebaceous hyperplasia'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" colspan="2"|'''Sebaceous hyperplasia'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 273: Line 275:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Lichen planus-like keratosis'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" colspan="2"|'''Lichen planus-like keratosis'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 286: Line 288:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Seborrheic keratosis'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" colspan="2"|'''Seborrheic keratosis'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 299: Line 301:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Actinic keratosis'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" colspan="2"|'''Actinic keratosis'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 312: Line 314:
| style="background: #F5F5F5; padding: 5px;" |painful
| style="background: #F5F5F5; padding: 5px;" |painful
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Nodular malignant melanoma'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" colspan="2"|'''Nodular malignant melanoma'''
| style="background: #F5F5F5; padding: 5px;" |Usually asymptomatic
| style="background: #F5F5F5; padding: 5px;" |Usually asymptomatic
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 327: Line 329:
* Genetic component in some cases with a positive family history
* Genetic component in some cases with a positive family history
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Amelanotic melanoma'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" colspan="2"|'''Amelanotic melanoma'''
| style="background: #F5F5F5; padding: 5px;" |Usually asymptomatic
| style="background: #F5F5F5; padding: 5px;" |Usually asymptomatic
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |

Revision as of 00:19, 19 February 2019

Diseases Clinical manifestations Para-clinical findings Additional findings
Symptoms Skin Examination
Lab Findings Histopathology
Symptoms Symptoms Dermoscopic Findings Skin exam 1 Skin exam 2 Skin exam 3 Risk factors Areas affected Unique features
Cutaneous squamous cell carcinoma in situ (Bowen's disease) Invasive squamous cell carcinoma
  • Usually asymptomatic
  • Well-demarcated, scaly patch or plaque
  • Hyperkeratotic, or ulcerative lesions
  • Lesions are often erythematous but can also be skin colored or pigmented.
  • none
  • Any cutaneous surface, including the head, neck, trunk, extremities, oral mucosa, shoulders, chest and back
  • In fair-skinned individuals, SCCs most commonly arise in sites frequently exposed to the sun
  • In black individuals, common sites for SCC include the legs, anus, and areas of chronic inflammation or scarring
  • Keratinocytic dysplasia involving the full thickness of the epidermis without infiltration of atypical cells into the dermis
  • The keratinocytes are pleomorphic with hyperchromatic nuclei, and numerous mitoses are present.
  • SCC in situ lesions tend to grow slowly, enlarging over the course of years
Invasive squamous cell carcinoma
  • Usually asymptomatic
  • White circles, keratin, blood spots, and white structureless zones
  • Well-differentiated lesions usually appear as indurated or firm, hyperkeratotic papules, plaques, or nodules
  • Poorly differentiated lesions are usually fleshy, soft, granulomatous papules or nodules that lack the hyperkeratosis that is often seen in well-differentiated lesions
  • Poorly differentiated tumors may have ulceration, hemorrhage, or areas of necrosis.
  • none
  • same as above
same as above same as above same as above
Keratoacanthoma Usually asymptomatic White circles, keratin, blood spots, and white structureless zones Initial lesion: small pink macule

Later: papular quality and eventually forms a circumscribed nodule.

The periphery of the nodule tends to be skin-colored or mildly erythematous and may have accompanying telangiectasias The center of the nodule typically demonstrates a prominent keratinous core.
  • Skin color
  • Ultraviolet radiation
  • Genetics
  • Drug exposure (BRAF inhibitors)
  • Trauma (surgery, laser therapy, cryotherapy or accidental trauma)
  • Chemical carcinogens (tar, pitch, polyaromatic hydrocarbons)
  • Human papillomavirus infection
  • Develops on sun-exposed areas of the skin.
  • The face (especially the eyelids, nose, cheek, and lower lip), neck, hands, and arms are common sites for involvement
a history of rapid growth within weeks favors this diagnosis
  • Epidermal hyperplasia with large eosinophilic keratinocytes
  • Central invagination with a keratotic core (in later stages)
  • "Lipping" or "buttressing" of the epidermis over the peripheral rim of the central keratotic plug
  • Sharp demarcation between the tumor and the surrounding stroma
  • Mixed inflammatory infiltrate in the dermis
  • It is controversial whether keratoacanthomas represent a subtype of well-differentiated SCC or a separate entity
Merkel cell carcinoma Usually asymptomatic Milky red areas; linear, irregular vessels; and polymorphous vessels rapidly growing, painless, firm, nontender, shiny, flesh-colored or bluish-red, intracutaneous nodule No more additional findings No more additional findings Older patients with light skin tones
  • Starts on areas of skin exposed to the sun
  • Most frequent locations for the primary tumor are head and neck, upper limbs and shoulder, lower limbs and hip, and trunk
  • Strands or nests of monotonously uniform, round, blue cells, containing large basophilic nuclei with powdery dispersed chromatin and inconspicuous nucleoli, and minimal cytoplasm
  • Single-cell necrosis, frequent mitoses, lymphovascular invasion, perineural invasion, and epidermal involvement via pagetoid spread.
Blue-red, dome-shaped nodule
Nodular basal cell carcinoma Usually asymptomatic Pearly papule with telangiectasias Pink or flesh-colored papule No more additional findings none Typically presents on the face May have a "rolled" border, where the periphery is more raised than the middle. Ulceration is frequent, and the term "rodent ulcer" refers to these ulcerated nodular BCCs
Superficial basal cell carcinoma Scaly patch Erythematous lesion No more additional findings
  • large, hyperchromatic, oval nuclei and little cytoplasm
  • well differentiated and cells appear histologically similar to basal cells of the epidermis
Prurigo nodules Usually asymptomatic Firm, dome-shaped and itchy ranging in size from a few millimeters to several centimeters and often symmetrically distributed Nodules can be flesh-colored, erythematous, or brown/black none
  • Extensor surfaces of the arms and legs and on the trunk
  • Upper back, abdomen, and sacrum
Worsened by heat, sweating, or irritation from clothing
  • Thick, compact orthohyperkeratosis
  • Irregular epidermal hyperplasia or pseudoepitheliomatous hyperplasia
  • Focal parakeratosis with irregular acanthosis
  • Diminished nerve fiber density
  • A nonspecific dermal infiltrate containing lymphocytes, macrophages, eosinophils, and neutrophils
Nodules range in number from few to hundreds

upper midback area is usually spared

Common nevus
  • Comma-shaped or curved vessels
  • Structureless skin-colored to light brown background pigmentation
  • Residual brown globules (clods) or brown thick circles, mainly located around the hair follicles can sometimes be seen
  • Dome-shaped, usually nonpigmented or hypopigmented nodules with a smooth surface
  • Terminal hairs are often present
Blue nevus
  • Structureless blue pigmentation
  • Structureless blue and white or blue and brown on some occasions
  • Bluish macules or papules
  • Head and neck,
  • Dorsal aspect of the distal extremities
  • Sacral area
Spitz nevus coiled vessels and a white network (also called reticular depigmentation or negative network) over a pink to reddish background benign, indolent melanocyte proliferation that most commonly develops in children, adolescents, and young adults.
Solar lentigo
Lentigo Maligna
Lentigo Maligna Melanoma
Sebaceous hyperplasia
Lichen planus-like keratosis
Seborrheic keratosis
Actinic keratosis less pigmentation, and tend to be somewhat smaller in size. Erythema Hyperkeratosis painful
Nodular malignant melanoma Usually asymptomatic Lump that has been rapidly growing over the past weeks No more additional findings No more additional findings none Cells proliferate downwards through the skin (vertical growth)
  • Two-thirds arise in normal skin, the rest in existing moles
  • Genetic component in some cases with a positive family history
Amelanotic melanoma Usually asymptomatic Color usually pink, purple or normal skin color Usually have an asymmetrical shape with an irregular border Red, nonspecific lesion with slightly elevated borders
  • Do not make melanin, so lesions are not pigmented

SCC in situ: Frequently, there is associated thickening of the epidermis (acanthosis), as well as hyperkeratosis and parakeratosis of the stratum corneum. In contrast to SCC in situ, actinic keratoses demonstrate only partial-thickness epidermal dysplasia.